Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Inclusion Criteria

• •1. Age must be ≥ 18 months and \< 21 years
• •2. Diagnosis of DIPG or high-grade glioma originating from the brainstem.
• •3. Lansky (for research participants ≤ 16 years) or Karnofsky (for research participants \> 16 years) performance score ≥ 40 at the time of study enrollment
• •4. Adequate organ function at the time of study enrollment as follows:
• •* Bone marrow: ANC ≥ 1,000/μL, platelet count ≥ 100,000/μL (transfusion independent), hemoglobin concentration ≥ 8g/dL (may be transfused)
• •* Renal: Serum creatinine concentration \< 2x the institutional normal values for age or GFR \> 70ml/min/1.73m2
• •* Hepatic: Total bilirubin concentration \< 1.5x the institutional upper limit of normal for age; SGPT \< 5x the institutional upper limit of normal; albumin ≥ 2 g/dL
• •5. Electrocardiogram (EKG) with an average QTc interval \< 450 msec. If a research participant has QTc interval ≥ 450 msec on screening EKG, the screening EKG may be repeated twice (at least 24 hours apart). The average QTc interval from the three screening EKGs must be \< 450 msec in order for the research participant to be eligible for the study. Research participants with abnormal serum electrolytes and a QTc interval ≥ 450 msec should have a repeat EKG repeated once the concentration of serum electrolyte is corrected
• •6. Female research participants of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of treatment start) or breast-feeding.
• •7. Female research participants of childbearing age and male research participants of child fathering potential must agree to use safe contraceptive methods